Here's Why The New Coronavirus Variant Won't Harm Pfizer's Stock

With Pfizer (NYSE: PFE) raking in $13 billion in sales of its coronavirus vaccine called Comirnaty in the third quarter alone, it's entirely understandable for investors to be skittish about the rapidly evolving threat posed by the new omicron variant. If omicron is as dastardly as early reports suggest, it may well pose a major challenge to vaccinated people and vaccine makers everywhere. Let's examine why Pfizer shareholders shouldn't be too concerned about the impact of omicron on their investment.